ZYUS Life Sciences Announces LIFE Offering of a minimum of C$15 Million and maximum of C$16 Million of Units

Executive Summary

• ZYUS Life Sciences Corp. launched a brokered private placement (“LIFE Offering”) of 23,809,523 – 25,396,825 Units at C$0.63 per Unit, targeting minimum gross proceeds of C$15 M and up to C$16 M.
• Each Unit consists of one common share and half a warrant; warrants allow purchase of an additional share at C$0.85 for 24 months.
• Net proceeds will fund the completion of Phase 2a clinical trials for Trichomylin® softgel capsules, preparation for Phase 2b, and general working capital.

Key Details

• Units Offered: Minimum 23,809,523; maximum 25,396,825 Units.
• Offering Price: C$0.63 per Unit.
• Gross Proceeds: Minimum C$15,000,000; Maximum up to C$16,000,000.
• Unit Composition:
• 1 common share of ZYUS.
• ½ warrant (each whole warrant gives the holder the right to purchase one additional common share at C$0.85).
• Warrant Terms: Exercise price C$0.85; exercisable for 24 months from issuance.
• Lead Agent & Bookrunner: Canaccord Genuity Corp., acting as sole lead agent and sole bookrunner.
• Agent Compensation:
• Cash commission of 5.0% of gross proceeds plus warrants equal to 5.0% of Units sold.
• For “President’s List” subscriptions up to C$5 M: reduced cash commission 2.5% and warrant compensation 2.5%.
• Lead Agent Additional Fee:
• Cash fee of 2.0% of gross proceeds.
• Corporate finance warrants equal to 2.0% of Units sold (excluding President’s List).
• Use of Proceeds:
• Advance clinical development of Trichomylin® softgel capsules (complete Phase 2a, prepare for Phase 2b).
• Working capital and general corporate purposes.
• Regulatory Exemptions: Offered under NI 45‑106 “LIFE Exemption” to Canadian investors (excluding Québec) and via U.S. private placement exemptions where applicable. No hold period required in Canada.
• Closing Date Expected: On or about January 29, 2026, subject to regulatory approvals.
• Listing Information: Common shares trade on the TSX Venture Exchange under ticker “ZYUS”.

Notable Quotes

• “The disclosure in this news release has been approved by Brent Zettl, Chief Executive Officer and Director of the Company.” – CEO Brent Zettl.